Returns Breakdown
| Return on Investment | 16.12 | |
| Return on Assets | (0.0195) | |
| Return on Equity | 0.28 | |
| Return Capital | 0.0123 | |
| Return on Sales | 0.0154 |
Is American Renal (NYSE:ARA) outlook positive for November 2020?
 | By Vlad Skutelnik | Macroaxis Story |
American Renal Average Assets are projected to increase significantly based on the last few years of reporting. The past year's Average Assets were at 1.12 Billion. The current year Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to grow to about 59.3 M, whereas Net Income Per Employee is forecasted to decline to (2.8 K). This short post will go over American Renal as a possible investment alternative for your portfolios. We will provide a perspective on American Renal future direction.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Rifka Kats
American Renal holds a performance score of 9 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.6938, which signifies possible diversification benefits within a given portfolio. Let's try to break down what American's beta means in this case. As returns on the market increase, American Renal returns are expected to increase less than the market. However, during the bear market, the loss on holding American Renal will be expected to be smaller as well. Although it is vital to follow American Renal Assoc historical returns, it is good to be conservative about what you can do with the information regarding equity current trending patterns. Our philosophy in foreseeing future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if American Renal Associates expected return of 1.13 will be sustainable into the future, we have found twenty-eight different technical indicators, which can help you to check if the expected returns are sustainable. Use American Renal treynor ratio, expected short fall, and the relationship between the jensen alpha and potential upside to analyze future returns on American Renal.
How important is Amer Renal's Liquidity
Amer Renal financial leverage refers to using borrowed capital as a funding source to finance Amer Renal Assoc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Amer Renal financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Amer Renal's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Amer Renal's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Amer Renal's total debt and its cash.
A Deeper Perspective
The current price rise of American Renal Assoc could raise concerns from investors as the firm it trading at a share price of 11.52 on slow start in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in November. The stock standard deviation of daily returns for 30 days investing horizon is currently 8.65. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the American Renal partners.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Amer Renal Assoc. Please refer to our Terms of Use for any information regarding our disclosure principles.